No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
UNITED KINGDOM— ViiV Healthcare has received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommending the marketing authorization of Triumeq PD,…
Read More
SOUTH AFRICA – Medicines manufacturer Aspen Pharmacare recommends that African companies be given licenses to manufacture HIV prevention drugs so as to be more accessible and affordable. An HIV prevention…
Read More
USA —ViiV Healthcare is assembling a diverse coalition of consumer businesses in a new White House-backed effort to eradicate HIV by the end of the decade. The new US Business…
Read More
SWITZERLAND – GlaxoSmithKline’s ViiV Healthcare has committed to grant voluntary license on the patents for its injectable HIV prevention drug to make it more widely available in poorer nations, where…
Read More
USA – Viiv Healthcare, a specialist HIV company majority-owned by GlaxoSmithKline with Pfizer and Japan’s Shionogi as shareholders, has settled a global patent infringement lawsuit with Gilead Sciences. The case…
Read More
USA – The U.S. Food and Drug Administration has approved ViiV Healthcare’s HIV treatment Cabenuva for use every two months, which means patients only need to receive an injectable dose…
Read More
USA – Vir Biotechnology and the Bill & Melinda Gates Foundation have collaborated to develop broadly neutralizing antibodies with a vaccinal effect for HIV treatment and malaria prevention. According to…
Read More
USA – Gilead Sciences, Inc. and Merck have temporarily suspended enrollment in a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir as…
Read More
USA – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK) has agreed to collaborate with Shionogi on the development of ultra-long acting HIV drugs that could…
Read More
UK – ViiV Healthcare, a global specialist HIV that is majorly owned by GlaxoSmithKline plc have announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE…
Read More